UPDATE: MLV & Co Initiates Buy, $4 Target on Zalicus

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

MLV & Co initiates coverage on Zalicus (NASDAQ: ZLCS) with a Buy rating and a $4 target price to reflect the company's clinical development for 2012. MLV & Co says, "looking ahead to the company's 2012 clinical developments for their drug candidates for pain and inflammation. The company has initiated two Phase I programs for their ion channel blockers this month, and aims to follow in mid-2012 with Phase II studies. Their lead candidate, Synavive is currently in Phase IIb. In addition to their current large pharmaceutical partnerships, we see Zalicus forming new collaborations for these clinical-stage products.ZLCS closed at $1.21 per share on Tuesday.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!